Archivum Immunologiae et Therapiae Experimentalis

, Volume 58, Issue 5, pp 347–354

Genetic Modification of T Cells Improves the Effectiveness of Adoptive Tumor Immunotherapy

REVIEW

DOI: 10.1007/s00005-010-0091-0

Cite this article as:
Jakóbisiak, M. & Gołąb, J. Arch. Immunol. Ther. Exp. (2010) 58: 347. doi:10.1007/s00005-010-0091-0

Abstract

Appropriate combinations of immunotherapy and gene therapy promise to be more effective in the treatment of cancer patients than either of these therapeutic approaches alone. One such treatment is based on the application of patients’ cytotoxic T cells, which can be activated, expanded, and genetically engineered to recognize particular tumor-associated antigens (TAAs). Because T cells recognizing TAAs might become unresponsive in the process of tumor development as a result of tumor evasion strategies, immunogenic viral antigens or alloantigens could be used for the expansion of cytotoxic T cells and then redirected through genetic engineering. This therapeutic approach has already demonstrated promising results in melanoma patients and could be used in the treatment of many other tumors. The graft-versus-leukemia, or more generally graft-versus-tumor, reaction based on the application of a donor lymphocyte infusion can also be ameliorated through the incorporation of suicide genes into donor lymphocytes. Such lymphocytes could be safely and more extensively used in tumor patients because they could be eliminated should a severe graft-versus-host reaction develop.

Keywords

Adoptive tumor immunotherapy Gene therapy Graft-versus-tumor 

Abbreviations

CAR

Chimeric antigen receptor

CD

Cluster of differentiation

CML

Chronic myelogenous leukemia

DLI

Donor lymphocyte infusion

GVH

Graft-versus-host

GVHD

Graft-versus-host disease

GVL

Graft-versus-leukemia

GVT

Graft-versus-tumor

HSV-tk

Herpes simplex thymidine kinase

IL

Interleukin

LMO-2

LIM domain-only

MHC

Major histocompatibility complex

NK

Natural killer

TAA

Tumor-associated antigen

TCR

T-cell receptor

TIL

Tumor-infiltrating lymphocyte

Copyright information

© L. Hirszfeld Institute of Immunology and Experimental Therapy, Wroclaw, Poland 2010

Authors and Affiliations

  1. 1.Department of Immunology, Centre of Biostructure ResearchMedical University of WarsawWarsawPoland

Personalised recommendations